DROFEN's Research-Driven Approach To Pen Injector Assembly Engineering

 

Most pharmaceutical equipment companies are built by mechanical engineers. DROFEN was built by a researcher who became an engineer.

Our Managing Director, Jordan Xu (Zhu Xu), began his career in a materials science laboratory at Shanghai Normal University, where his graduate research on long-lasting phosphorescent materials produced two SCI-indexed publications: one in Materials Letters (Elsevier, Impact Factor ≈ 2.9) on Hf⁴⁺-doped zinc silicate afterglow phosphors, and one in Luminescence (Wiley, Impact Factor ≈ 2.9) on a novel bluish-white afterglow phosphor, β-Zn₃(PO₄)₂:Hf⁴⁺.

 

That academic training - the discipline of hypothesis formation, controlled experimentation, and data-driven conclusions - became the engineering philosophy behind every DROFEN assembly system.

 

In 2009, Jordan founded DROFEN in Shanghai with a conviction that pharmaceutical equipment engineering should be treated as an applied science, not merely a trade. Seventeen years later, that conviction has produced a body of published work unusual for an equipment manufacturer:

 

Full publication record:  https://orcid.org/0009-0000-2077-2241

 

Every DROFEN patent and publication addresses a real engineering problem encountered during commercial production. This is not theoretical work - it is applied science validated on the factory floor.

 

The cartridge press-fit operation in pen injector assembly is the highest-risk step: a glass cartridge must be inserted into the device body with precisely controlled force. Too little force and the cartridge loosens during use; too much and the glass cracks - destroying a component worth $5–50 in API value.

 

Our published research on force-displacement envelope monitoring led to a patented servo-controlled press station that captures the complete force profile of every insertion. Each unit is individually verified against a validated acceptance envelope in real time. This is not sampling-based quality control - it is 100% in-process verification informed by published mechanical analysis.

 

Electronic batch records in high-speed assembly (160 pens per minute) present a unique data integrity challenge: the system must capture, store, and protect thousands of data points per minute while maintaining ALCOA+ compliance.

Our ongoing research into data integrity architecture for combination product assembly - currently under peer review at the Journal of Pharmaceutical Innovation (Springer) - directly informs the unified S7 PLC platform used in DROFEN assembly lines. Every record is attributable, legible, contemporaneous, original, and accurate by design, not by aftermarket software patches.

 

How do you prove that an in-line inspection system reliably catches defective products? Our published methodology uses deliberately manufactured challenge parts - components with known, calibrated defects - to validate detection capability with statistical confidence. This approach, documented in our technical white papers, provides the evidence base that regulatory auditors require during process validation.

 

We believe that publishing research openly - rather than relying solely on trade secrets - creates a stronger company:

For our clients: Published design rationale means faster validation, stronger regulatory submissions, and auditable engineering decisions. When an FDA inspector asks "why did you set this parameter at this value?", the answer is supported by peer-reviewed data.

For the industry: Pharmaceutical manufacturing advances when knowledge is shared. The pen injector assembly field is still young enough that published best practices benefit everyone - including us, through the credibility and relationships that open contribution builds.

For recruitment: Engineers who publish attract engineers who want to publish. Our research program helps us recruit technical talent that a pure manufacturing company cannot.

 

DROFEN's research program continues with multiple works in progress:

We welcome collaboration with pharmaceutical manufacturers, CDMOs, academic institutions, and regulatory professionals working on injectable device manufacturing challenges.